D. E. Shaw & Co., Inc. Madrigal Pharmaceuticals, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $98.6 Billion
- Q2 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 44,900 shares of MDGL stock, worth $9.36 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
44,900
Previous 52,800
14.96%
Holding current value
$9.36 Million
Previous $14.1 Million
10.78%
% of portfolio
0.01%
Previous 0.01%
Shares
21 transactions
Others Institutions Holding MDGL
# of Institutions
299Shares Held
22MCall Options Held
757KPut Options Held
370K-
Janus Henderson Group PLC London, X02.49MShares$518 Million0.38% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.06MShares$428 Million7.86% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$412 Million7.35% of portfolio
-
Rtw Investments, LP New York, NY1.92MShares$399 Million8.96% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.85MShares$386 Million39.74% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $3.56B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...